show all | hide all No of entries

Information on EC 1.1.1.51 - 3(or 17)beta-hydroxysteroid dehydrogenase and Organism(s) Homo sapiens

for references in articles please use BRENDA:EC1.1.1.51
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
IUBMB Comments
Also acts on other 3beta- or 17beta-hydroxysteroids. cf. EC 1.1.1.209 3(or 17)alpha-hydroxysteroid dehydrogenase.
Specify your search results
The word/phrase is now marked yellow!
Select one or more organisms in this record:
This record set is specific for:
Homo sapiens
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria
The taxonomic range for the selected organisms is: Homo sapiens
Synonyms
3 beta-hydroxysteroid dehydrogenase, 17 beta-hydroxysteroid dehydrogenase, 17beta-hydroxysteroid dehydrogenase, 3betahsd, hsd17b3, 17beta-hydroxysteroid dehydrogenases, 17beta-hsd3, 17beta-hsd2, 17betahsd2, 17beta-hsd type 2, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
17-ketoreductase
-
-
-
-
17beta-HSD
-
-
17beta-HSD type 2
-
-
17beta-HSD type 3
-
-
17beta-HSD-3
-
-
17beta-HSD2
-
-
17beta-HSD3
17beta-HSD5
-
-
17beta-HSD7_2
-
-
17beta-HSOR
-
-
17beta-hydroxy steroid dehydrogenase
-
-
-
-
17beta-hydroxysteroid dehydrogenase
-
-
17beta-hydroxysteroid dehydrogenase 2
-
-
17beta-hydroxysteroid dehydrogenase type 3
17beta-hydroxysteroid dehydrogenases type 2
-
-
17beta-hydroxysteroid oxidoreductase
-
-
17betaHSD2
-
-
3beta,17beta-hydroxysteroid dehydrogenase
-
-
-
-
3beta-HSD
-
-
3beta-hydroxy steroid dehydrogenase
-
-
-
-
3beta-hydroxysteroid dehydrogenase
3beta-hydroxysteroid dehydrogenase/DELTA5-4-isomerase
-
-
3beta-hydroxystroid oxidoreductase
-
-
-
-
3beta17betaHSDH
-
-
-
-
aldo keto reductase 1C3
-
beta-hydroxy steroid dehydrogenase
-
-
-
-
dehydrogenase, 17beta-hydroxy steroid
-
-
-
-
dehydrogenase, 3beta-hydroxy steroid
-
-
-
-
dehydrogenase, beta-hydroxy steroid
-
-
-
-
DELTA5-3beta-HSD
-
-
DELTA5-3beta-hydroxysteroid dehydrogenase
-
-
form 2 type 7 17beta-hydroxysteroid dehydrogenase
-
-
steroid 17beta-reductase
-
-
-
-
type 17beta-HSD
-
-
type 2 17beta-HSD
-
-
type 3 17beta-HSD
-
-
type 3 17beta-hydroxysteroid dehydrogenase
-
-
type 5 17-beta-hydroxysteroid dehydrogenase
-
additional information
-
the enzyme belongs to the short-chain alcohol dehydrogenase family
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
oxidation
redox reaction
reduction
SYSTEMATIC NAME
IUBMB Comments
3(or 17)beta-hydroxysteroid:NAD(P)+ oxidoreductase
Also acts on other 3beta- or 17beta-hydroxysteroids. cf. EC 1.1.1.209 3(or 17)alpha-hydroxysteroid dehydrogenase.
CAS REGISTRY NUMBER
COMMENTARY hide
9015-81-0
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
11beta-hydroxyandrost-5-ene-3,17-dione + NADPH
11beta,17beta-dihydroxyandrost-5-ene-3-one + NADP+
show the reaction diagram
-
i.e. 11beta-hydroxy-androstenedione, reduction at C17
i.e. 11beta-testosterone
-
?
17-oxo steroids + NADPH
?
show the reaction diagram
-
maintenance of balance between oxidized and reduced steroids in blood
-
-
-
20alpha-dihydroprogesterone + NAD+
4-pregnen-3alpha,20beta-diol + NADH
show the reaction diagram
-
-
-
-
r
20alpha-dihydroprogesterone + NADP+
4-pregnen-3alpha,20beta-diol + NADPH
show the reaction diagram
-
-
-
-
r
20alpha-hydroxypregn-4-en-3-one + NADP+
progesterone + NADPH
show the reaction diagram
-
-
-
r
4-androstene-3,17-dione + NADPH + H+
testosterone + NADP+
show the reaction diagram
5-androstenedione + NADPH
5alpha-dihydrotestosterone + NADP+
show the reaction diagram
-
isozyme 17beta-HSD3
-
-
r
androst-4-ene-3,17-dione + NADPH
testosterone + NADP+
show the reaction diagram
-
-
-
-
?
androst-5-ene-3,11,17-trione + NADPH
17beta-hydroxyandrost-5-ene-3,11-dione + NADP+
show the reaction diagram
-
i.e. 11-ketoandrostenedione, reduction at C17
i.e. 11-keto-testosterone
-
?
androst-5-ene-3beta,17beta-diol + NADP+
dehydroepiandrosterone + NADPH
show the reaction diagram
-
-
-
r
androstane-3,17-dione + NADPH
dihydrotestosterone + NADP+
show the reaction diagram
-
-
-
-
?
androstanedione + NADPH
dihydrotestosterone + NADP+
show the reaction diagram
-
reduction at C17
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
show the reaction diagram
androsterone + NADPH
androstane-3beta,17beta-diol + NADP+
show the reaction diagram
-
reduction at C17
-
-
?
dehydroepiandrosterone + NAD+
4-androstene-3,17-dione + NADH + H+
show the reaction diagram
-
-
-
-
?
dehydroepiandrosterone + NAD+
androstene-3,17-dione + NADH + H+
show the reaction diagram
-
-
-
-
?
dehydroepiandrosterone + NADPH
5-androstene-3beta,17beta-diol + NADP+
show the reaction diagram
-
reduction at C17
-
-
?
dehydroepiandrosterone + NADPH + H+
androst-5-ene-3beta,17beta-diol + NADP+
show the reaction diagram
-
-
-
-
?
dihydroepiandrostendione + NADPH
dihydrotestosterone + NADP+
show the reaction diagram
-
-
-
-
?
dihydrotestosterone + NAD+
5alpha-androstan-3,17-dione + NADH
show the reaction diagram
-
-
-
-
r
dihydrotestosterone + NADP+
5alpha-androstan-3,17-dione + NADPH
show the reaction diagram
-
-
-
-
r
dihydrotestosterone + NADPH + H+
5alpha-androstane-3beta,17beta-diol + NADP+
show the reaction diagram
-
androsterone inactivation
-
-
?
epiandrosterone + NADPH
5-androstane-3beta,17beta-diol + NADP+
show the reaction diagram
-
reduction at C17
-
-
?
estradiol + NAD(P)+
estrone + NAD(P)H
show the reaction diagram
-
-
-
-
?
estradiol + NAD+
estrone + NADH
show the reaction diagram
-
-
-
-
?
estradiol + NADP+
estrone + NADPH
show the reaction diagram
estradiol sulfate + NADP+
estrone sulfate + NADPH
show the reaction diagram
-
-
-
?
estrone + NADPH
estradiol + NADP+
show the reaction diagram
-
estrogen activation
-
-
?
testosterone + NAD(P)+
androst-4-en-3,17-dione + NAD(P)H + H+
show the reaction diagram
testosterone + NAD(P)+
androstenedione + NAD(P)H + H+
show the reaction diagram
testosterone + NAD+
androst-4-en-3,17-dione + NADH
show the reaction diagram
-
-
-
-
r
testosterone + NADP+
androst-4-en-3,17-dione + NADPH
show the reaction diagram
-
-
-
-
r
testosterone + NADP+
androstenedione + NADPH + H+
show the reaction diagram
zymosterone + NADPH
zymosterol + NADP+
show the reaction diagram
-
-
-
-
?
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
17-oxo steroids + NADPH
?
show the reaction diagram
-
maintenance of balance between oxidized and reduced steroids in blood
-
-
-
4-androstene-3,17-dione + NADPH + H+
testosterone + NADP+
show the reaction diagram
-
isozymes 17beta-HSD3 and 17beta-HSD5
-
-
r
5-androstenedione + NADPH
5alpha-dihydrotestosterone + NADP+
show the reaction diagram
-
isozyme 17beta-HSD3
-
-
r
androst-4-ene-3,17-dione + NADPH
testosterone + NADP+
show the reaction diagram
-
-
-
-
?
androstane-3,17-dione + NADPH
dihydrotestosterone + NADP+
show the reaction diagram
-
-
-
-
?
androstenedione + NADPH + H+
testosterone + NADP+
show the reaction diagram
-
-
-
-
r
dihydrotestosterone + NADPH + H+
5alpha-androstane-3beta,17beta-diol + NADP+
show the reaction diagram
-
androsterone inactivation
-
-
?
estrone + NADPH
estradiol + NADP+
show the reaction diagram
-
estrogen activation
-
-
?
testosterone + NAD(P)+
androstenedione + NAD(P)H + H+
show the reaction diagram
testosterone + NADP+
androstenedione + NADPH + H+
show the reaction diagram
zymosterone + NADPH
zymosterol + NADP+
show the reaction diagram
-
-
-
-
?
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
NADP+
NADPH
additional information
-
no activity with NADH in the forward reaction, poor activity with NAD+ in the reverse raection, overview
-
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2,4-dihydroxyphenyl)-phenylmethanone
-
remaining 17beta HSD3 activity: 1.1%
(3a,5a)-3-[[(2R,5S)-4-[[5-(dimethylamino)naphthalen-1-yl]sulfonyl]-2,5-dimethylpiperazin-1-yl]methyl]-17-methylideneandrostan-3-ol
-
-
(3alpha,5alpha)-3-([(2R,5S)-2,5-dimethyl-4-[2-(trifluoromethyl)benzene-1-sulfonyl]piperazin-1-yl]methyl)-3-hydroxyandrostan-17-one
-
i.e. RM-532-105
(4-(2,4-dichlorophenyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(2-chlorophenyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(2-methoxyphenyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(3-chlorophenyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(4-(methylsulfonyl)phenyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(4-bromophenyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(4-chloro-2-(hydroxymethyl)phenyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(4-chloro-2-methylphenyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(4-chlorobenzoyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(4-chlorobenzyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(4-chlorophenyl)-1,4-diazepan-1-yl)(morpholino)methanone
-
-
(4-(4-chlorophenyl)piperazin-1-yl)(1-oxido-4-thiomorpholino)methanone
-
-
(4-(4-chlorophenyl)piperazin-1-yl)(3,4-dihydroisoquinolin-2(1H)-yl)methanone
-
-
(4-(4-chlorophenyl)piperazin-1-yl)(4-(2-hydroxyethyl)piperazin-1-yl)methanone
-
-
(4-(4-chlorophenyl)piperazin-1-yl)(4-methylpiperazin-1-yl)methanone
-
-
(4-(4-chlorophenyl)piperazin-1-yl)(cyclohexyl)methanone
-
-
(4-(4-chlorophenyl)piperazin-1-yl)(morpholino)methanethione
-
-
(4-(4-chlorophenyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(4-chlorophenyl)piperazin-1-yl)(phenyl)methanone
-
-
(4-(4-chlorophenyl)piperazin-1-yl)(piperidin-1-yl)methanone
-
-
(4-(4-chlorophenyl)piperazin-1-yl)(pyridin-4-yl)methanone
-
-
(4-(4-chlorophenyl)piperazin-1-yl)(tetrahydro-2H-pyran-4-yl)methanone
-
-
(4-(4-chlorophenyl)piperazin-1-yl)(thiomorpholino)methanone
-
-
(4-(4-ethynylphenyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(4-fluorophenyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(4-iodophenyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(4-methoxyphenyl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(6-bromopyridin-2-yl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(6-chloropyridin-3-yl)piperazin-1-yl)(morpholino)methanone
-
-
(4-(biphenyl-4-yl)piperazin-1-yl)(morpholino)methanone
-
-
(5-(4-chlorophenyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)(morpholino)methanone
-
-
(S)-ibuprofen
-
-
1-(11,12-dihydro-6H-dibenzo[b,f]oxocin-12-yl)ethanone
-
IC50: 0.00297 mM
1-(4-(4-(4-chlorophenyl)piperazine-1-carbonyl)piperazin-1-yl)-2-hydroxyethanone
-
-
1-(4-(4-chlorophenyl)piperazine-1-carbonyl)piperidine-4-carboxylic acid
-
-
1-(5,6,11,12-tetrahydrodibenzo[b,f]azocin-12-yl)ethanone
-
IC50: 0.00474 mM
1-[(3R,5S,8R,9S,10S,13S,14S)-10,13-dimethyl-2',17-dioxohexadecahydro-3'H-spiro[cyclopenta[a]phenanthrene-3,5'-[1,3]oxazolidin]-3'-yl]-3-(morpholin-4-yl)propan-2-yl cyclohexanecarboxylate
-
-
1-[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]ethanone
-
IC50: 0.02 nM
1-[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]methanamine
-
IC50: 0.00024 mM; IC50: 0.00029 mM
11-[3-hydroxy-17-beta-hydroxyestr-5(10)-en-17alpha-yl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-7-yl]-undecanoic acid butyl-methyl-amide
-
selective inhibition of type 2 17beta-HSD
12-acetyl-1-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.0115 mM
12-acetyl-11,12-dihydro-2-(trifluoromethyl)-6H-dibenzo(b,f)(1,4)thiazocine
-
-
12-acetyl-11,12-dihydro-6H-dibenzo(b,f)(1,4)thiazocine
-
-
12-acetyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocin-3-ol
-
IC50: 0.0049 mM
12-acetyl-2,3-dichloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00001 mM
12-acetyl-2-(trifluoromethyl)-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00281 mM
12-acetyl-2-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00003 mM
12-acetyl-3,4-dichloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00076 mM
12-acetyl-3-bromo-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00025 mM
12-acetyl-3-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00010 mM
12-acetyl-3-fluoro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.00009 mM
12-acetyl-3-methoxy-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.0021 mM
12-acetyl-3-methyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
-
IC50: 0.001 mM
17-hydroxy-7alpha-thioethyl-3-oxo-4-androstene-17alpha-propionic acid, gamma-lactone
-
IC50 for reduction of androst-4-en-3,17-dione: 0.0009 mM
17alpha-ethynyl-estradiol
-
0.01 mM, 54% inhibition, reaction with 0.002 mM estradiol; inhibits oxidation of testosterone
17beta-dihydroequilin
-
0.01 mM, 88% inhibition, reaction with 0.002 mM estradiol
2,2',4,4'-tetrahydroxybenzophenone
-
remaining 17beta HSD3 activity: 47%
2,5-dioxo-3-(2-propyn-1-yl)-3-pyrrolidinecarboxylic acid 2,3,3-triphenyl-2-propen-1-yl-ester
-
-
2-((3-chloro-4-hydroxybenzoyl)amino)-N-(2-(2-methoxyphenyl)ethyl)-5-phenoxy-benzamide
-
-
2-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo(b,f)azocin-8-yl)-benzoic acid methyl ester
-
-
2-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
-
IC50: 3 nM
2-hydroxy-estradiol
-
0.01 mM, 67% inhibition, reaction with 0.002 mM estradiol
20alpha-dihydroprogesterone
-
0.01 mM, 71% inhibition, reaction with 0.002 mM estradiol, inhibits oxidation of testosterone
3,4-dihydrobenzoic acid
-
0.001 mM, 40% inhibition, reduction of androst-4-en-3,17-dione
3-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzamide
-
-
3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
-
IC50: 3 nM
3-benzylidene camphor
-
remaining 17beta HSD3 activity: 56%
3-hydroxy-1,3,5(10)-estratriene-17beta-O,17alpha-butanolactone
-
selective for type 2 17beta-HSD versus types 1, 3, and 7 but not versus type 5 17beta-HSD
3-oxo-17alpha-pregna-4-ene-7alpha-(benzylthia)-21,17-carbolactone
-
IC50 for reduction of androst-4-en-3,17-dione: 0.00042 mM,IC50 for oxidation of testosterone: 0.001 mM
3-oxo-17alpha-pregna-4-ene-7alpha-(phenylthia)-21,17-carbolactone
-
IC50 for reduction of androst-4-en-3,17-dione: 0.001 mM
3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone
-
IC50 for reduction of androst-4-en-3,17-dione: 0.0011 mM; IC50 for reduction of androst-4-en-3,17-dione: 0.0014 mM
3-oxo-17alpha-pregna-4-ene-7alpha-[4-[2-(1-piperidinyl)-ethoxy]benzylthia]-21,17-carbolactone
-
IC50 for oxidation of testosterone: 0.0007 mM, no inhibition of type 1, 3 and 5 17beta-HSD, nor against P450 aromatase
3alpha-alkylated androsterone derivatives
-
17-88% inhibition at 0.003 mM, overview
-
3alpha-butyl-3-hydroxy-5alpha-androstan-17-one
-
-
3alpha-ether-3beta-substituted androsterone derivatives
-
diverse derivatives, IC50: 70-760 nM, overview
-
3beta-alkylated androsterone derivatives
-
IC50: 57-147 nM
-
3beta-cyclohexylethyl-androsterone
-
-
3beta-hexyl-androsterone
-
-
3beta-phenyl-androsterone
-
mixed-type inhibition, shows some proliferative activity on AR+ and Er+ cell lines not mediated through androgen or estrogen receptors
3beta-phenylethyl-3alpha-methyl-O-androsterone
-
IC50: 73 nM
3beta-phenylethyl-androsterone
3beta-phenylmethyl-androsterone
3beta-substituted androsterone derivatives
-
IC50: 57-147 nM
-
4-((4-(4-chlorophenyl)piperazin-1-yl)sulfonyl)morpholine
-
-
4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzamide
-
-
4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzoic acid
-
-
4-(4-chlorophenyl)-N-cyclohexylpiperazine-1-carboxamide
-
-
4-(4-chlorophenyl)-N-phenylpiperazine-1-carboxamide
-
-
4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)-N-methylbenzamide
-
IC50: 25 nM
4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
-
IC50: 5 nM
4-MA
-
-
4-methylbenzylidene camphor
-
remaining 17beta HSD3 activity: 33%
4-[4-(4-chlorophenyl)piperazine-1-carbonyl]-thiomorpholine-1,1-dione
-
-
5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.00007 mM
5-acetyl-2-chloro-5,6-dihydro-dibenzo(b,f)azocine
-
-
5-acetyl-2-chloro-5,6-dihydrodibenzo[b,f]azocine
-
IC50: 0.00024 mM
5-acetyl-2-chloro-8-(2-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 3 nM
5-acetyl-2-chloro-8-(3-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 8 nM
5-acetyl-2-chloro-8-(4-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 2 nM
5-acetyl-2-chloro-8-phenyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 4 nM
5-acetyl-3-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.00005 mM
5-acetyl-5,6,11,12-tetrahydro-dibenzo(b,f)(1,4)diazocine
-
-
5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-amine
-
IC50: 0.00049 mM
5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine-9-carboxamide
-
IC50: 0.001 mM
5-acetyl-8-bromo-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 9 nM
5-acetyl-8-phenyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.02 nM
5-acetyl-9-bromo-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 7 nM
5-acetyl-N-cyclohexyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-amine
-
IC50: 8 nM
5alpha-androstane-3alpha,17beta-diol
-
0.01 mM, 87% inhibition, reaction with 0.002 mM estradiol
5alpha-dihydrotestosterone
-
inhibits oxidation of testosterone
5beta-androstane-3alpha,17beta-diol
-
0.01 mM, 83% inhibition, reaction with 0.002 mM estradiol
5beta-dihydrotestosterone
-
inhibits oxidation of testosterone
9-bromo-11,12-dihydrodibenzo[b,f]azocine-5(6H)-carboxamide
-
IC50: 0.00028 mM
9-bromo-5-butanoyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.00032 mM
9-bromo-5-ethyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
-
IC50: 0.001 mM
9-cis-retinoic acid
-
weak
albumin
-
-
-
androsterone
-
-
beta-octylglucoside
-
strong
chloromercuribenzene-p-sulfonic acid
-
-
cyproterone acetate
-
-
danazol
-
inhibits oxidation of testosterone, 0.01 mM, 83% inhibition
dibenzothiazocine
-
IC50: 0.0004 mM
dodecyl-beta-D-maltoside
-
inhibition above 0.5%
EM-919
-
a 17beta-HSD type 2 inhibitor
epostane
-
-
estradiol
-
inhibits oxidation of testosterone
Flufenamic acid
-
-
flurbiprofen
-
-
gallic acid
-
0.001 mM, 50% inhibition, reduction of androst-4-en-3,17-dione
GTx-560
-
competitively and selectively inhibits AKR1C3-dependent androgen receptor transactivation. GTx-560 completely blocks the formation of testosterone from androstenedione, indicating the ability of AKR1C3 inhibitors, unlike 5alpha-reductase inhibitors, to reduce testosterone levels
indomethacin
-
-
Meclofenamic acid
-
-
methyl 12-acetyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine-3-sulfinate
-
IC50: 0.01 mM
methyl 3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzoate
-
IC50: 0.00004 mM
methyl 4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzoate
-
-
methyl 4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzoate
-
IC50: 0.00004 mM; IC50: 0.7 nM
methyl [3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]amidosulfite
-
IC50: 0.00014 mM
methyl [4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]amidosulfite
-
IC50: 2 nM
morpholino(4-(2-(trifluoromethyl)phenyl)piperazin-1-yl)methanone
-
-
morpholino(4-(4-nitrophenyl)piperazin-1-yl)methanone
-
-
morpholino(4-(naphthalen-2-yl)piperazin-1-yl)methanone
-
-
morpholino(4-(o-tolyl)piperazin-1-yl)methanone
-
-
morpholino(4-(p-tolyl)piperazin-1-yl)methanone
-
-
morpholino(4-(quinolin-3-yl)piperazin-1-yl)methanone
-
-
morpholino(4-phenylpiperazin-1-yl)methanone
-
-
-
morpholino-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)methanone
-
-
N,N-dimethyl-4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzamide
-
-
N-(((3,5)-3-hydroxy-17-oxoandrostan-3-yl)methyl)-N-(tricyclo(3.3.1.13.7)dec-2-ylmethyl)butanamide
-
-
N-(4-(4-(morpholine-4-carbonyl)piperazin-1-yl)phenyl)acetamide
-
-
N-(4-(4-(morpholine-4-carbonyl)piperazin-1-yl)phenyl)methanesulfonamide
-
-
N-(5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-yl)benzamide
-
IC50: 0.00016 mM
N-methyl-4-(4-(morpholine-4-carbonyl)piperazin-1-yl)benzamide
-
-
naproxen
-
-
oleuropein glycoside
-
0.001 mM, 40% inhibition, reduction of androst-4-en-3,17-dione
p-chloromercuribenzoate
-
-
RM-532-105
-
-
spiro-gamma-lactone-estradiol
-
inhibits the reduction of androst-4-en-3,17-dione, reversible, IC50: 0.00025 mM
spironolactone
-
IC50 for oxidation of testosterone: 0.0011 mM
Strogen forte
-
standardized extract of the plant Sabalis serrulata, 0.212 mg/ml result in 50% enzyme inhibition
-
testosterone
-
0.01 mM, 70% inhibition, reaction with 0.002 mM estradiol
tetrahydrodibenzazocine
-
IC50: 0.00009 mM
thiomorpholine
-
-
Triton X-100
-
significant
[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]methanol
-
IC50: 0.9 nM
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
R1881
-
requires amino acids 1-282 of AKR1C3 to elicit its coactivation, inhibitor GTx-560 requires the full-length AKR1C3 to bind and inhibit R1881-induced activity
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00053
20alpha-dihydroprogesterone
-
pH 7.4, with NAD+ as cofactor
0.00001
dehydroepiandrosterone
-
37°C, pH not specified in the publication
0.00025
dihydrotestosterone
-
pH 7.4, with NAD+ as cofactor
0.00035
estradiol
-
pH 7.4, with NAD+ as cofactor
0.11 - 0.167
NAD+
0.0053 - 0.0056
NADH
9.6
NADP+
-
pH 7.4, reaction with estradiol
0.00061 - 0.24
testosterone
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.78
20alpha-dihydroprogesterone
-
pH 7.4, with NAD+ as cofactor
2.4
dihydrotestosterone
-
pH 7.4, with NAD+ as cofactor
3.9
estradiol
-
pH 7.4, with NAD+ as cofactor
2.9 - 4.7
NAD+
0.27 - 0.33
NADH
1.3
NADP+
-
pH 7.4, reaction with estradiol
3.4
testosterone
-
pH 7.4, with NAD+ as cofactor
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0003
17alpha-ethynyl-estradiol
-
-
0.0006
danazol
-
-
0.0008
estradiol
-
-
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.001
(2,4-dihydroxyphenyl)-phenylmethanone
Homo sapiens
-
pH 7.4, 37°C
0.000262
(3a,5a)-3-[[(2R,5S)-4-[[5-(dimethylamino)naphthalen-1-yl]sulfonyl]-2,5-dimethylpiperazin-1-yl]methyl]-17-methylideneandrostan-3-ol
Homo sapiens
-
pH and temperature not specified in the publication
0.000085
(3alpha,5alpha)-3-([(2R,5S)-2,5-dimethyl-4-[2-(trifluoromethyl)benzene-1-sulfonyl]piperazin-1-yl]methyl)-3-hydroxyandrostan-17-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00297
1-(11,12-dihydro-6H-dibenzo[b,f]oxocin-12-yl)ethanone
Homo sapiens
-
IC50: 0.00297 mM
0.00474
1-(5,6,11,12-tetrahydrodibenzo[b,f]azocin-12-yl)ethanone
Homo sapiens
-
IC50: 0.00474 mM
0.00000002
1-[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]ethanone
Homo sapiens
-
IC50: 0.02 nM
0.00024 - 0.00029
1-[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]methanamine
0.0115
12-acetyl-1-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.0115 mM
0.00281
12-acetyl-11,12-dihydro-2-(trifluoromethyl)-6H-dibenzo(b,f)(1,4)thiazocine
Homo sapiens
-
pH and temperature not specified in the publication
0.0004
12-acetyl-11,12-dihydro-6H-dibenzo(b,f)(1,4)thiazocine
Homo sapiens
-
pH and temperature not specified in the publication
0.0049
12-acetyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocin-3-ol
Homo sapiens
-
IC50: 0.0049 mM
0.00001
12-acetyl-2,3-dichloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.00001 mM
0.00281
12-acetyl-2-(trifluoromethyl)-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.00281 mM
0.00003
12-acetyl-2-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.00003 mM
0.00076
12-acetyl-3,4-dichloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.00076 mM
0.00025
12-acetyl-3-bromo-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.00025 mM
0.0001
12-acetyl-3-chloro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.00010 mM
0.00009
12-acetyl-3-fluoro-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.00009 mM
0.0021
12-acetyl-3-methoxy-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.0021 mM
0.001
12-acetyl-3-methyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine
Homo sapiens
-
IC50: 0.001 mM
0.0009
17-hydroxy-7alpha-thioethyl-3-oxo-4-androstene-17alpha-propionic acid, gamma-lactone
Homo sapiens
-
IC50 for reduction of androst-4-en-3,17-dione: 0.0009 mM
0.0181
2,2',4,4'-tetrahydroxybenzophenone
Homo sapiens
-
pH 7.4, 37°C
0.00915
2,5-dioxo-3-(2-propyn-1-yl)-3-pyrrolidinecarboxylic acid 2,3,3-triphenyl-2-propen-1-yl-ester
Homo sapiens
-
pH and temperature not specified in the publication
0.00006
2-((3-chloro-4-hydroxybenzoyl)amino)-N-(2-(2-methoxyphenyl)ethyl)-5-phenoxy-benzamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00000002
2-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo(b,f)azocin-8-yl)-benzoic acid methyl ester
Homo sapiens
-
pH and temperature not specified in the publication
0.000003
2-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
Homo sapiens
-
IC50: 3 nM
0.000003
3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
Homo sapiens
-
IC50: 3 nM
0.033
3-benzylidene camphor
Homo sapiens
-
pH 7.4, 37°C
0.001
3-oxo-17alpha-pregna-4-ene-7alpha-(benzylthia)-21,17-carbolactone
Homo sapiens
-
IC50 for reduction of androst-4-en-3,17-dione: 0.00042 mM,IC50 for oxidation of testosterone: 0.001 mM
0.001
3-oxo-17alpha-pregna-4-ene-7alpha-(phenylthia)-21,17-carbolactone
Homo sapiens
-
IC50 for reduction of androst-4-en-3,17-dione: 0.001 mM
0.0011 - 0.0014
3-oxo-17alpha-pregna-4-ene-7alpha-(propylthia)-21,17-carbolactone
0.0007
3-oxo-17alpha-pregna-4-ene-7alpha-[4-[2-(1-piperidinyl)-ethoxy]benzylthia]-21,17-carbolactone
Homo sapiens
-
IC50 for oxidation of testosterone: 0.0007 mM, no inhibition of type 1, 3 and 5 17beta-HSD, nor against P450 aromatase
0.000116
3alpha-butyl-3-hydroxy-5alpha-androstan-17-one
Homo sapiens
-
pH and temperature not specified in the publication
0.00007 - 0.00076
3alpha-ether-3beta-substituted androsterone derivatives
Homo sapiens
-
diverse derivatives, IC50: 70-760 nM, overview
-
0.000057 - 0.000147
3beta-alkylated androsterone derivatives
Homo sapiens
-
IC50: 57-147 nM
-
0.000073
3beta-phenylethyl-3alpha-methyl-O-androsterone
Homo sapiens
-
IC50: 73 nM
0.000099
3beta-phenylethyl-androsterone
Homo sapiens
-
IC50: 99 nM
0.000057
3beta-phenylmethyl-androsterone
Homo sapiens
-
IC50: 57 nM
0.000057 - 0.000147
3beta-substituted androsterone derivatives
Homo sapiens
-
IC50: 57-147 nM
-
0.000025
4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)-N-methylbenzamide
Homo sapiens
-
IC50: 25 nM
0.000005
4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzonitrile
Homo sapiens
-
IC50: 5 nM
0.00000145
4-MA
Homo sapiens
-
37°C, pH not specified in the publication
0.0107
4-methylbenzylidene camphor
Homo sapiens
-
pH 7.4, 37°C
0.00007
5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 0.00007 mM
0.00024
5-acetyl-2-chloro-5,6-dihydro-dibenzo(b,f)azocine
Homo sapiens
-
pH and temperature not specified in the publication
0.00024
5-acetyl-2-chloro-5,6-dihydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 0.00024 mM
0.000003
5-acetyl-2-chloro-8-(2-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 3 nM
0.000008
5-acetyl-2-chloro-8-(3-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 8 nM
0.000002
5-acetyl-2-chloro-8-(4-methoxyphenyl)-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 2 nM
0.000004
5-acetyl-2-chloro-8-phenyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 4 nM
0.00005
5-acetyl-3-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 0.00005 mM
0.00474
5-acetyl-5,6,11,12-tetrahydro-dibenzo(b,f)(1,4)diazocine
Homo sapiens
-
pH and temperature not specified in the publication
0.00049
5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-amine
Homo sapiens
-
IC50: 0.00049 mM
0.001
5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine-9-carboxamide
Homo sapiens
-
IC50: 0.001 mM
0.000009
5-acetyl-8-bromo-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 9 nM
0.00000002
5-acetyl-8-phenyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 0.02 nM
0.000007
5-acetyl-9-bromo-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 7 nM
0.000008
5-acetyl-N-cyclohexyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-amine
Homo sapiens
-
IC50: 8 nM
0.00028
9-bromo-11,12-dihydrodibenzo[b,f]azocine-5(6H)-carboxamide
Homo sapiens
-
IC50: 0.00028 mM
0.00032
9-bromo-5-butanoyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 0.00032 mM
0.001
9-bromo-5-ethyl-5,6,11,12-tetrahydrodibenzo[b,f]azocine
Homo sapiens
-
IC50: 0.001 mM
0.000182
androsterone
Homo sapiens
-
pH and temperature not specified in the publication
0.00015
cyproterone acetate
Homo sapiens
-
37°C, pH not specified in the publication
0.0004
dibenzothiazocine
Homo sapiens
-
IC50: 0.0004 mM
0.0000062
epostane
Homo sapiens
-
37°C, pH not specified in the publication
0.01
methyl 12-acetyl-11,12-dihydro-6H-dibenzo[b,f][1,4]thiazocine-3-sulfinate
Homo sapiens
-
IC50: 0.01 mM
0.00004
methyl 3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzoate
Homo sapiens
-
IC50: 0.00004 mM
0.0000007 - 0.00004
methyl 4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)benzoate
0.00014
methyl [3-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]amidosulfite
Homo sapiens
-
IC50: 0.00014 mM
0.000002
methyl [4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]amidosulfite
Homo sapiens
-
IC50: 2 nM
0.000035
N-(((3,5)-3-hydroxy-17-oxoandrostan-3-yl)methyl)-N-(tricyclo(3.3.1.13.7)dec-2-ylmethyl)butanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00016
N-(5-acetyl-5,6,11,12-tetrahydrodibenzo[b,f]azocin-9-yl)benzamide
Homo sapiens
-
IC50: 0.00016 mM
0.00025
spiro-gamma-lactone-estradiol
Homo sapiens
-
inhibits the reduction of androst-4-en-3,17-dione, reversible, IC50: 0.00025 mM
0.0011
spironolactone
Homo sapiens
-
IC50 for oxidation of testosterone: 0.0011 mM
0.00009
tetrahydrodibenzazocine
Homo sapiens
-
IC50: 0.00009 mM
0.0000009
[4-(5-acetyl-2-chloro-5,6,11,12-tetrahydrodibenzo[b,f]azocin-8-yl)phenyl]methanol
Homo sapiens
-
IC50: 0.9 nM
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.00000000935
-
female abdominal skin, mean value, n=4, 37°C, pH not specified in the publication
0.0000000122
-
male inguinal skin, mean value, n=8, 37°C, pH not specified in the publication
0.0000000213
-
female perineal skin, mean value, n=4, 37°C, pH not specified in the publication
additional information
-
determination of serum and tumor tissue concentrations of steroids in prostate cancer patients, overview
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.2
-
assay at
7.4
-
assay at
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
37
-
assay at
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
derived from an epidermoid carcinoma of the vulva
Manually annotated by BRENDA team
-
real-time RT-PCR expression 17beta-HSD type 2 analysis
Manually annotated by BRENDA team
-
male abdominal, 17beta-HSD type 2 is localized in the vasculature of the adipose compartment, real-time RT-PCR expression analysis
Manually annotated by BRENDA team
-
EpiskinTM is a cultured human epidermis. 17beta-hydroxysteroid dehydrogenase and 3alpha-hydroxysteroid dehdyrogenase activities are present at moderate levels in EpiskinTM, while 3beta-hydroxysteroid dehdyrogenase activity is low
Manually annotated by BRENDA team
-
real-time RT-PCR expression 17beta-HSD type 2 analysis
Manually annotated by BRENDA team
-
isozyme 17beta-HSD5
Manually annotated by BRENDA team
-
-
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
evolution
-
the enzyme belongs to the AKR1C family
malfunction
-
AKR1C3 siRNA reduces androgen receptor signaling in VCaP cells. Small-molecule inhibitors inhibit both the enzymatic and coactivator functions of AKR1C3 resulting in androgen-dependent prostate cancer and CRPC regression
metabolism
-
the enzyme catalyzes the last step in the biosynthesis of the potent androgen testosterone (T), by stereoselectively reducing the C17 ketone of 4-androstene-3,17-dione (4-dione), with NADPH as cofactor
physiological function
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
Sequence
HCD2_HUMAN
261
0
26923
Swiss-Prot
AK1C3_HUMAN
323
0
36853
Swiss-Prot
DHB3_HUMAN
310
3
34516
Swiss-Prot
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
42300
-
2 * 42300, SDS-PAGE
64000
-
gel filtration
90400
-
glycerol gradient ultracentrifugation
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
dimer
-
2 * 42300, SDS-PAGE
CRYSTALLIZATION/commentary
ORGANISM
UNIPROT
LITERATURE
enzyme with inhibitor (4-(4-chlorophenyl)piperazin-1-yl)(morpholino)methanone bound in the actie site, X-ray diffraction structure determination and analysis, docking study and modelling
-
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
-
AKR1C3 siRNA reduces androgen receptor signaling in VCaP cells
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-15°C, a few percent loss of activity in several months
-
4°C, activity in both the homogenate and the supernatant using dodecyl-beta-D-maltoside as detergent can be kept for several days without significant loss of activity
-
PURIFICATION/commentary
ORGANISM
UNIPROT
LITERATURE
His6-tagged 17beta-HSD2 overexpressed in Sf9 cells
-
partial
-
CLONED/commentary
ORGANISM
UNIPROT
LITERATURE
AKR1C3, quantitative enzyme expression analysis by real-time PCR, recombinant expression in HEK-293 cells
-
DNA and amino acid sequence determination and analysis, chromosome metaphase, interphase mapping, i.e. FISH mapping, localization on chromosome 10q11.2, stable expression in HEK-293 cells
-
DNA and amino acid sequence determination and analysis, phylogenetic tree, transient expression in HEK-293 cells
-
expressed in HEK-293 cells by transient transfection
-
gene HSD17B2, quantitative real-time RT-PCR enzyme expression analysis
-
gene HSD17B3, recombinant expression in HEK-293 cells
-
His6-tagged 17beta-HSD2 overexpressed in Sf9 cells
-
overexpression in HEK-293 cells
-
overexpression of type 3 17beta-HSD in HEK-293 cells
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
drug development
-
the steroidogenic enzyme 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3) is a therapeutic target in the management of androgen-sensitive diseases such as prostate cancer and benign prostate hyperplasia
medicine
-
inhibitor Strogen forte extract can be used for treatment of benign prostatic hyperplasia
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Mulder, E.; Lamers-Stahlhofen, G.J.M.; van der Molen, H.J.
Isolation and characterization of 17beta-hydroxy steroid dehydrogenase from human erythrocytes
Biochem. J.
127
649-659
1972
Homo sapiens
Manually annotated by BRENDA team
Khan, N.; Sharma, K.K.; Andersson, S.; Auchus, R.J.
Human 17beta-hydroxysteroid dehydrogenases types 1, 2, and 3 catalyze bi-directional equilibrium reactions, rather than unidirectional metabolism, in HEK-293 cells
Arch. Biochem. Biophys.
429
50-59
2004
Homo sapiens
Manually annotated by BRENDA team
Poirier, D.
Inhibitors of 17beta-hydroxysteroid dehydrogenases
Curr. Med. Chem.
10
453-477
2003
Homo sapiens, Rattus norvegicus
Manually annotated by BRENDA team
Lu, M.L.; Huang, Y.W.; Lin, S.X.
Purification, reconstitution, and steady-state kinetics of the trans-membrane 17beta-hydroxysteroid dehydrogenase 2
J. Biol. Chem.
277
22123-22130
2002
Homo sapiens
Manually annotated by BRENDA team
Tchedam Ngatcha, B.; Luu-The, V.; Labrie, F.; Poirier, D.
Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship
J. Med. Chem.
48
5257-5268
2005
Homo sapiens
Manually annotated by BRENDA team
Mindnich, R.; Haller, F.; Halbach, F.; Moeller, G.; Hrabe de Angelis, M.; Adamski, J.
Androgen metabolism via 17beta-hydroxysteroid dehydrogenase type 3 in mammalian and non-mammalian vertebrates: comparison of the human and the zebrafish enzyme
J. Mol. Endocrinol.
35
305-316
2005
Danio rerio, Danio rerio (Q6QA32), Homo sapiens
Manually annotated by BRENDA team
Liu, H.; Robert, A.; Luu-The, V.
Cloning and characterization of human form 2 type 7 17beta-hydroxysteroid dehydrogenase, a primarily 3beta-keto reductase and estrogen activating and androgen inactivating enzyme
J. Steroid Biochem. Mol. Biol.
94
173-179
2005
Homo sapiens
Manually annotated by BRENDA team
Ngatcha, B.T.; Laplante, Y.; Labrie, F.; Luu-The, V.; Poirier, D.
3beta-Alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines
Mol. Cell. Endocrinol.
248
225-232
2006
Homo sapiens
Manually annotated by BRENDA team
Luu-The, V.; Tremblay, P.; Labrie, F.
Characterization of type 12 17beta-hydroxysteroid dehydrogenase, an isoform of type 3 17beta-hydroxysteroid dehydrogenase responsible for estradiol formation in women
Mol. Endocrinol.
20
437-443
2006
Homo sapiens
Manually annotated by BRENDA team
Fink, B.E.; Gavai, A.V.; Tokarski, J.S.; Goyal, B.; Misra, R.; Xiao, H.; Kimball, S.D.; Han, W.; Norris, D.; Spires, T.E.; You, D.; Gottardis, M.M.; Lorenzi, M.V.; Vite, G.D.
Identification of a novel series of tetrahydrodibenzazocines as inhibitors of 17beta-hydroxysteroid dehydrogenase type 3
Bioorg. Med. Chem. Lett.
16
1532-1536
2006
Homo sapiens
Manually annotated by BRENDA team
Degtyar, V.G.; Babkina, T.V.; Kazantseva, I.A.; Morozov, A.P.; Trapeznikova, M.F.; Kushlinskii, N.E.
Reductase activity of 17beta-hydroxysteroid oxidoreductase in prostatic tumors of different histological structure
Bull. Exp. Biol. Med.
139
715-717
2005
Homo sapiens
Manually annotated by BRENDA team
Lukacik, P.; Kavanagh, K.L.; Oppermann, U.
Structure and function of human 17beta-hydroxysteroid dehydrogenases
Mol. Cell. Endocrinol.
248
61-71
2006
Homo sapiens
Manually annotated by BRENDA team
Luu-The, V.; Ferraris, C.; Duche, D.; Belanger, P.; Leclaire, J.; Labrie, F.
Steroid metabolism and profile of steroidogenic gene expression in Episkin: high similarity with human epidermis
J. Steroid Biochem. Mol. Biol.
107
30-36
2007
Homo sapiens
Manually annotated by BRENDA team
Chura, J.C.; Ryu, H.S.; Simard, M.; Poirier, D.; Tremblay, Y.; Brooker, D.C.; Blomquist, C.H.; Argenta, P.A.
Steroid-converting enzymes in human ovarian carcinomas
Mol. Cell. Endocrinol.
301
51-58
2009
Homo sapiens
Manually annotated by BRENDA team
Nashev, L.G.; Schuster, D.; Laggner, C.; Sodha, S.; Langer, T.; Wolber, G.; Odermatt, A.
The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals
Biochem. Pharmacol.
79
1189-1199
2010
Homo sapiens, Homo sapiens (P37058), Mus musculus, Rattus norvegicus
Manually annotated by BRENDA team
Tóth, I.; Szécsi, M.; Julesz, J.; Faredin, I.; Behnke, B.
In vitro inhibition of testicular delta 5-3 beta-hydroxysteroid dehydrogenase and prostatic 5 alpha-reductase activities in rats and humans by strogen forte extract
Int. Urol. Nephrol.
28
337-348
1996
Homo sapiens, Rattus norvegicus, Rattus norvegicus Wistar
Manually annotated by BRENDA team
Tóth, I.; Szécsi, M.; Julesz, J.; Faredin I.
Activity and inhibition of 3-beta-hydroxysteroid dehydrogenase/delta-5-4-isomerase in human skin
Skin Pharmacol. Physiol.
10
160-168
1997
Homo sapiens
Manually annotated by BRENDA team
Kenmogne, L.C.; Maltais, R.; Poirier, D.
Synthesis of a dansyl-labeled inhibitor of 17beta-hydroxysteroid dehydrogenase type 3 for optical imaging
Bioorg. Med. Chem. Lett.
26
2179-2183
2016
Homo sapiens
Manually annotated by BRENDA team
Flanagan, J.U.; Atwell, G.J.; Heinrich, D.M.; Brooke, D.G.; Silva, S.; Rigoreau, L.J.; Trivier, E.; Turnbull, A.P.; Raynham, T.; Jamieson, S.M.; Denny, W.A.
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-beta-hydroxysteroid dehydrogenase (AKR1C3)
Bioorg. Med. Chem.
22
967-977
2014
Homo sapiens (P42330)
Manually annotated by BRENDA team
Yepuru, M.; Wu, Z.; Kulkarni, A.; Yin, F.; Barrett, C.M.; Kim, J.; Steiner, M.S.; Miller, D.D.; Dalton, J.T.; Narayanan, R.
Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth
Clin. Cancer Res.
19
5613-5625
2013
Homo sapiens, Homo sapiens (P42330)
Manually annotated by BRENDA team
Roy, J.; Fournier, M.A.; Maltais, R.; Kenmogne, L.C.; Poirier, D.
Reprint of in vitro and in vivo evaluation of a 3beta-androsterone derivative as inhibitor of 17beta-hydroxysteroid dehydrogenase type 3
J. Steroid Biochem. Mol. Biol.
153
170-178
2015
Homo sapiens (P37058), Rattus norvegicus (O54939), Rattus norvegicus Sprague-Dawley (O54939)
Manually annotated by BRENDA team
Mansour, M.F.; Pelletier, M.; Boulet, M.-M.; Mayrand, D.; Brochu, G.; Lebel, S.; Poirier, D.; Fradette, J.; Cianflone, K.; Luu-The, V.; Tchernof, A.
Oxidative activity of 17beta-hydroxysteroid dehydrogenase on testosterone in male abdominal adipose tissues and cellular localization of 17beta-HSD type 2
Mol. Cell. Endocrinol.
414
168-176
2015
Homo sapiens
Manually annotated by BRENDA team
Select items on the left to see more content.